References
- De Hoog GS. Risk assessment of fungi reported from hu-mans and animals. Mycoses 1996; 39: 407–417.
- Barnes AJ, Denning DW. Aspergilli: significance as pathogens. Rev Med Microbiol 1993; 4: 176–80.
- Ruchel R, Reichard U. Pathogenesis and clinical presenta-tion of aspergillosis. Contrib Microbiol 1999; 2: 21–3.
- Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26: 781–803.
- Chi C, Fung C, Liu C. Aspergillus flavus epidural abscess and osteomyelitis in a diabetic patient. J Microbiol Immunol In-fect 2003; 36: 145–8.
- Vinas FC, King PK, Diaz FG. Spinal Aspergillus osteo-myelitis. Clin Infect Dis 1999; 28: 1223–9.
- Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: re-view of published in vitro and in vivo interactions and 6281 clin-ical cases from 1966 to 2001. Clin Infect Dis 2003; 37 (Suppl 3): 188–224.
- Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 696–709.
- Kirby A, Hassan I, Burnie J. Recommendations for man-aging Aspergillus osteomyelitis and joint infections based on a review of the literature. J Infect 2006; 52: 405–14.
- Herbrecht R, Denning DW, Patterson TF, et al. Voricona-zole versus amphotericin B for primary therapy of invasive as-pergillosis. N Engl J Med 2002; 347: 408–415.
- Ruhnke M. Voriconazole — application and perspectives. Mycoses 2002; 45: 42–47.
- Sabo JA, Abdel-Rahman SM. Voriconazole: a new tria-zole antifungal Ann Pharmacother 2000; 34: 1032-1043.
- Mouas H, Lutsar I, Dupont B, et al. Voriconazole for In-vasive Bone Aspergillosis: a Worldwide Experience of 20 Cases. Clin Infect Dis 2005; 40: 1141–7.
- Spanakis EK, Aperis G, Mylonakis E. New agents for the treatment of fungal infections: clinical efficacy and gaps in cov-erage. Clin Infect Dis 2006; 43: 1060–8.
- Chen SC and Sorrell TC. Antifungal agents. Med J Aust 2007; 187: 404–409.